FDA Rejects Summit Therapeutics and Akeso Lung Cancer Drug Ivonescimab Over Lack of Survival Benefit

The Food and Drug Administration has officially rejected the marketing application for ivonescimab, a promising but controversial bispecific antibody designed to treat advanced non-small cell lung cancer (NSCLC). Developed through a high-profile partnership between U.S.-based Summit Therapeutics and Chinese biopharmaceutical firm Akeso, the drug’s failure to secure regulatory clearance marks a significant blow to the companies’ ambitions in the competitive immuno-oncology landscape. In a complete response letter issued to the sponsors, the FDA explicitly cited the absence of a demonstrated overall survival (OS) benefit, noting that while the therapy showed success in delaying disease progression, it failed to provide the necessary clinical evidence to justify its risk-benefit profile for patients.
A Regulatory Standoff: The Clinical Data Gap
Ivonescimab, often described as a "bispecific" agent, is engineered to simultaneously target both PD-1—a protein that helps tumors hide from the immune system—and VEGF, a protein that facilitates blood vessel growth to nourish tumors. The clinical premise of the drug is that by dual-targeting these pathways, it can offer a more robust therapeutic response than traditional PD-1 inhibitors like Merck’s Keytruda.
However, the FDA’s decision hinges on a fundamental distinction in oncology trial endpoints: progression-free survival (PFS) versus overall survival (OS). While the clinical trials provided to regulators demonstrated that ivonescimab could extend the time patients lived without their cancer worsening, the agency maintained that this metric alone was insufficient. In the eyes of the FDA, a drug intended for use in advanced lung cancer must prove that it allows patients to live longer in absolute terms. Without a statistically significant improvement in overall survival, the agency concluded that the drug’s potential toxicity and side-effect profile—common with VEGF-targeting therapies—outweighed the clinical gains observed during the trial period.
Chronology of the Ivonescimab Development Path
The journey of ivonescimab has been marked by rapid clinical acceleration followed by this sobering regulatory reality check.

- 2022-2023: Akeso generates significant data in China, showing high efficacy rates in locally advanced or metastatic NSCLC. The partnership with Summit Therapeutics is formalized, granting Summit the rights to develop and commercialize the drug in the United States, Canada, Europe, and Japan.
- Early 2024: Summit Therapeutics reports positive data from the HARMONi-2 trial, a randomized Phase 3 study in China, which showed that ivonescimab outperformed pembrolizumab (Keytruda) in patients with PD-L1-positive NSCLC. This data set served as the cornerstone for the U.S. regulatory submission.
- Mid-2024: The FDA accepts the application for review, sparking optimism among investors and analysts that a new standard of care might be on the horizon.
- November 2026: The FDA delivers the final rejection, citing the lack of survival data, effectively stalling the drug’s U.S. market entry.
The Significance of the Overall Survival Mandate
The FDA’s rejection underscores a rigorous, ongoing shift in how the agency evaluates oncology drugs, particularly those that seek to challenge existing market leaders. In the current therapeutic landscape, where immunotherapy has become the bedrock of cancer treatment, the bar for "incremental" innovation has been raised.
For a new drug to disrupt the current standard of care, it must do more than just improve tumor shrinkage or delay the progression of the disease; it must demonstrate a tangible extension of life. This is particularly relevant for VEGF-targeting agents, which are historically associated with hypertension, proteinuria, and an increased risk of hemorrhage. The FDA’s stance is that if a patient is going to be exposed to these known toxicities, the drug must offer a clear, survival-based justification.
Implications for Summit Therapeutics and Akeso
The rejection poses a severe financial and strategic challenge for Summit Therapeutics. The company had bet its pipeline and capital allocation heavily on the success of ivonescimab. With the U.S. door closed for the time being, the company must now determine if it can design a new, longer-term study that includes overall survival as a primary endpoint. Such a study would require significant time, ranging from two to four years, and a substantial investment in capital.
For Akeso, the impact is similarly profound. While the drug remains an important component of the Chinese domestic market, the loss of a clear path to the U.S. market diminishes the global valuation of the asset. The partnership, which was touted as a model for U.S.-China biotech collaboration, will now be scrutinized by investors and industry observers who are concerned about the regulatory hurdles associated with bringing foreign-developed clinical data into the U.S. regulatory framework.
Industry Context and the "Standard of Care" Barrier
The oncology market is saturated with PD-1/PD-L1 inhibitors. The dominance of Merck’s Keytruda, Bristol Myers Squibb’s Opdivo, and other checkpoint inhibitors has created a high "hurdle rate" for new entrants. Any new drug entering this space is expected to either show superior survival outcomes or offer a significantly improved safety profile.

Industry experts note that this rejection serves as a warning to other biotechs attempting to use "surrogate endpoints"—like progression-free survival or tumor response rates—to secure rapid approvals. While the FDA has historically been more flexible under the Accelerated Approval pathway, that flexibility is increasingly restricted to diseases with high unmet needs where no alternative therapies exist. In the case of lung cancer, where multiple effective treatments are already available, the agency has signaled that it will not compromise on the requirement for overall survival evidence.
Looking Ahead: Potential Pathways to Approval
Following the announcement, stakeholders are looking toward the next steps for the companies. Summit Therapeutics has indicated they will review the FDA’s findings in detail. To move forward, the company has three potential strategies:
- New Pivotal Trials: Initiate a new global Phase 3 study that tracks patients until enough "events" (deaths) occur to satisfy the FDA’s statistical requirements for overall survival.
- Subgroup Analysis: Attempt to identify specific patient populations—such as those with high PD-L1 expression or specific genetic mutations—where the drug might show a more pronounced survival benefit, potentially requesting a focused approval.
- Combination Therapy Exploration: Pivot to testing ivonescimab in combination with other novel agents, hoping that a synergistic effect will provide the necessary clinical boost to justify approval.
However, each of these paths is fraught with uncertainty. The cost of running multi-year, large-scale oncology trials is immense, and there is no guarantee that a future study will yield the survival data the FDA is demanding.
Broader Market Impact
The news of the rejection has ripple effects across the biotech sector, particularly for companies relying on international clinical trial data to support FDA filings. It reinforces the necessity of aligning with the FDA’s expectations regarding trial design at the earliest possible stage. As the industry moves toward 2027, this event will likely be cited as a case study in the importance of prioritizing mortality-based endpoints over surrogate markers in oncology.
The rejection of ivonescimab is not merely a localized corporate setback; it is a signal to the broader pharmaceutical industry that the FDA remains committed to its mandate of protecting patient safety and ensuring that new therapies provide genuine clinical value. For Summit Therapeutics and Akeso, the immediate future involves navigating a difficult path of clinical re-evaluation, while for the oncology community, it serves as a reminder that the path from promising laboratory data to a clinically approved cancer treatment remains a marathon, not a sprint. The companies must now reconcile their ambitions with the sobering reality of the FDA’s standard for evidence-based medicine.







